Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer

@inproceedings{Endo2014ImmunohistochemicalDO,
  title={Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer},
  author={Yumi Endo and Hiroko Yamashita and Satoru Takahashi and Shinya Sato and Nobuyasu Yoshimoto and Tomoko Asano and Yukari Hato and Yu ‐ Ze Dong and Yoshitaka Fujii and Tatsuya Toyama},
  booktitle={BMC Cancer},
  year={2014}
}
There are many molecular differences between estrogen receptor α (ERα)-positive and ER-negative breast cancers. Recent analyses have shown that the former can be divided into two subtypes, luminal A and luminal B. These differ in response to endocrine therapy and chemotherapy, and in prognosis. In a previous study, we found that microRNA (miR)-1290 that was… CONTINUE READING